Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer
- 25 November 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 161 (2), 279-287
- https://doi.org/10.1007/s10549-016-4059-6
Abstract
The current American Joint Committee on Cancer (AJCC) staging manual uses tumor size, lymph node, and metastatic status to stage breast cancer across different subtypes. We examined the prognosis of triple-negative breast cancer (TNBC) versus non-TNBC within the same stages and sub-stages to evaluate whether TNBC had worse prognosis than non-TNBC. We reviewed the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) data and identified 158,358 patients diagnosed with breast cancer from 2010 to 2012. The overall survival (OS) time and breast cancer cause-specific survival time were compared between patients with TNBC and non-TNBC in each stage and sub-stages. The results were validated using a dataset of 2049 patients with longer follow-up from our institution. Compared with patients with non-TNBC, patients with TNBC had worse OS and breast cancer cause-specific survival time in every stage and sub-stage in univariate and multivariate analyses adjusting for age, race, tumor grade, and surgery and radiation treatments in the SEER data. The worse OS time in patients with TNBC was validated in our institutional dataset. Patients with TNBC have worse survival than patients with non-TNBC. The new AJCC staging manual should consider breast cancer biomarker information.Keywords
This publication has 24 references indexed in Scilit:
- GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomasHuman Pathology, 2015
- Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast CancerJournal of Clinical Oncology, 2015
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831Journal of Clinical Oncology, 2014
- Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer NetworkCancer, 2012
- Novel Staging System for Predicting Disease-Specific Survival in Patients With Breast Cancer Treated With Surgery As the First Intervention: Time to Modify the Current American Joint Committee on Cancer Staging SystemJournal of Clinical Oncology, 2011
- Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast CancerClinical Cancer Research, 2011
- Triple-Negative Breast CancerThe New England Journal of Medicine, 2010
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2010
- Epidemiology of basal-like breast cancerBreast Cancer Research and Treatment, 2007
- TNMCancer, 2001